Press Releases

Auris Medical Holding Ltd., a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and central nervous system disorders, today announced the launch of the development of AM-301, a drug-free nasal spray for protection against airborne pathogens and allergens, based on positive data obtained in a SARS-CoV-2 assay. In order to expedite the development process, Auris Medical set up a new subsidiary, Altamira Medica Ltd. (“Alta

Ripeta and Wellcome are pleased to announce a collaborative effort to assess data and code availability in the manuscripts of funded research projects. The project will analyze papers funded by Wellcome from the year prior to it establishing a dedicated Open Research team (2016) and from the most recent calendar year (2019). It supports Wellcome’s commitment to maximising the availability and re-use of results from its funded research. Ripeta, a Digital Science portf

Eisai Co., Ltd. announced today that it will take over by transfer the manufacturing and marketing approval of Parkinson's disease treatment Equfina 50mg TABLETS (safinamide mesilate, "Equfina") in Japan from Meiji Seika Pharma Co., Ltd., effective September 23, 2020. In Japan, Meiji conducted clinical studies of Equfina and obtained its manufacturing and marketing approval in September 2019. Eisai has exclusively sold Equfina in Japan as a distributor. Based on the li

Immune Regulation Ltd, a US and UK based clinical stage biotechnology company, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office (USPTO) for a new patent covering IRL201805 (‘1805). ‘1805 is a first-in-class compound derived from the endogenous immuno-regulatory protein Binding Immunoglobulin Protein (BiP) and is in development to treat rheumatoid arthritis and other inflammatory and autoimmune diseases. The new patent provides Im

Marinomed Biotech AG has applied for approval of the new decongestant Carragelose® nasal spray in a first group of EU countries. It is the first product from the Carragelose® platform to be approved as a medicinal product. The spray aims to treat viral infections of the respiratory tract and reduce the swelling of the mucous membranes of the nose and throat, which enables free breathing through the nose. “With this decongestant nasal spray, we are expanding our successful Carrag

RedHill Biopharma Ltd, a specialty biopharmaceutical company, today announced the selection of opaganib 1, a patented, first-class, orally administered selective sphingosine kinase-2 (SK2) inhibitor under evaluation for the treatment of severe pneumonia associated with COVID-19 disease, to receive a grant of 300,000 USD from the Pennsylvania State of Pennsylvania Vaccines, Treatments and Therapies (CV-VTT) COVID-19 Program, which aims to support rapid advancement of new COVID treatments -19.

Roche announced that the United States (US) Food and Drug Administration (FDA) has approved Gavreto™ (pralsetinib) for the treatment of adults with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC) as detected by an FDA approved test. This indication was approved under the FDA’s Accelerated Approval programme, based on data from the phase I/II ARROW study. Continued approval for this indication may be contingent upon verification an

BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through a portfolio built around gelsolin technology, announces publication of “Recombinant Human Plasma Gelsolin Improves Survival and Attenuates Lung Injury in a Murine Model of Multidrug-Resistant Pseudomonas aeruginosa Pneumonia.” Recombinant human plasma gelsolin (rhu-pGSN) is currently being studied in severe COVID-19 patients where lung i

Lodo Therapeutics Corp. (Lodo), a biotechnology company reinventing natural product drug discovery by applying its informatics-enabled technology platform to previously undruggable disease targets, today announced that it has completed the acquisition of Hibiskus BioPharma, Inc. (Hibiskus). In a related transaction, Lodo has acquired exclusive worldwide rights from the University of California, Riverside (UCR) and Michigan State University (MSU) to preclinical proteasome and immunoproteasome

Viome, a research-driven precision healthcare company, announced that it has expanded its collaboration with Mayo Clinic beyond the initial focus of obesity and insomnia. The focus of the expansion is to utilize Viome’s therapeutics platform to better understand the role of microbial, mitochondrial and human gene functions that lead to heart disease, and to explore the potential of Viome’s AI-driven personalized nutrition and other lifestyle changes in helping subsequent recovery